| Literature DB >> 7912225 |
J Bohn1, D Roggenbuck, U Settmacher, W Döcke, H D Volk, R Von Baehr, S Jahn.
Abstract
In a recent publication we described the binding of natural IgM antibodies derived from the human fetal B cell repertoire to the cell surface of some human tumor cells including colon carcinoma, small-cell lung cancer and B lymphoma lines [1]. Further analyses showed that a similar molecule was bound by the respective monoclonal human antibodies on the cell surface of polyclonally stimulated human CD3+ T cells, but is absent from unstimulated MNC. Both CD4+ and CD8+ stimulated cells were recognized. The molecule was found to be expressed together with lymphocyte activation markers (4F2, CD72, CD25). The membrane antigen expressed on both the activated T lymphocytes and tumor cells was characterized in a 2-D electrophoresis system: molecular weight 55-60 kDa, pI-approximately 6.0. Whereas the proliferation capacity of tumor cells was detected to be decreased significantly in the presence of the binding antibodies, no influence on [3H]thymidine uptake into stimulated T cells was found, suggesting different functional consequences of binding the respective antigen on malignant and normal cells. An interesting finding is the enhanced expression of major histocompatibility complex class I molecules on tumor cells incubated with human natural antibodies.Entities:
Mesh:
Substances:
Year: 1994 PMID: 7912225 DOI: 10.1016/0165-2478(94)90106-6
Source DB: PubMed Journal: Immunol Lett ISSN: 0165-2478 Impact factor: 3.685